Floatz logo

MDM2 INHIBITOR AMG-232

Secondary Acute Myeloid Leukemia

National Cancer Institute (NCI)Small moleculePhase 1Active
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
23/ 100
Competitive Position
81/ 100

Competitive context

78 Active assets in the Secondary Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BBB
FILGRASTIM
City of Hope Medical Center
Phase 2/3BBB
Idarubicine
Fred Hutchinson Cancer Center
Phase 2/3BB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

MDM2 INHIBITOR AMG-232 is also rated in:

small cell lung carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
Mantle Cell Lymphoma and Diffuse Large B Cell LymphomaDormant
CC
Indicative ·
41 / 100
View asset →
B-cell neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →